Journal of Hepatocellular Carcinoma
Scope & Guideline
Connecting the global community to hepatocellular carcinoma advancements.
Introduction
Aims and Scopes
- Clinical Research and Trials:
The journal publishes studies that investigate various clinical aspects of hepatocellular carcinoma, including treatment efficacy, patient outcomes, and therapeutic strategies across different patient demographics. - Molecular and Genetic Studies:
Research contributions often explore the molecular mechanisms underlying HCC, including genetic mutations, epigenetic modifications, and their implications for prognosis and treatment. - Imaging and Radiomics:
The journal emphasizes the role of advanced imaging techniques and radiomic analysis in predicting HCC progression, microvascular invasion, and treatment response. - Immunotherapy and Targeted Therapies:
A significant focus is placed on the development and clinical application of immunotherapeutic approaches and targeted therapies, particularly in combination with traditional treatments like transarterial chemoembolization. - Biomarkers and Prognostic Models:
Research on identifying novel biomarkers for early detection, prognosis, and treatment response prediction is a core area, aimed at enhancing personalized medicine in HCC. - Public Health and Disparities:
The journal also addresses healthcare disparities and the impact of socioeconomic factors on HCC treatment outcomes, contributing to a broader understanding of the disease in diverse populations.
Trending and Emerging
- Artificial Intelligence and Machine Learning:
Recent publications increasingly utilize AI and machine learning techniques for predictive modeling, enhancing diagnostic accuracy, and personalizing treatment strategies for HCC patients. - Combination Therapy Strategies:
There is a growing trend towards exploring combination therapies, particularly integrating immunotherapy with traditional treatments, reflecting the need for more effective and comprehensive treatment regimens. - Metabolic and Nutritional Factors:
Research examining the role of metabolic syndrome, nutrition, and specific metabolic pathways in HCC progression and treatment response is emerging as a significant area of interest. - Patient-Centered Care and Quality of Life:
Studies focused on patient-reported outcomes, quality of life, and healthcare disparities are becoming more prominent, indicating a shift towards a more holistic approach to HCC management. - Novel Biomarker Discovery:
There is an increased emphasis on identifying and validating novel biomarkers for early detection and monitoring treatment response, driven by advances in genomic and proteomic technologies.
Declining or Waning
- Traditional Chemotherapy Approaches:
Research focusing on conventional chemotherapy methods has decreased as newer targeted therapies and immunotherapies gain traction, reflecting a shift in treatment paradigms. - Single-Modality Treatments:
The emphasis on single-modality treatments, such as isolated surgical resection or standalone chemoembolization, is waning in favor of multimodal approaches that combine various therapies for improved outcomes. - Basic Science without Clinical Application:
There is a noticeable decline in studies that focus solely on basic science or laboratory findings without direct clinical relevance or application, as the journal increasingly prioritizes translational research. - Epidemiological Studies:
The frequency of purely epidemiological studies examining HCC incidence and prevalence is decreasing, possibly as the journal shifts towards more intervention-focused research.
Similar Journals
JTO Clinical and Research Reports
Innovating Solutions in Oncology and Pulmonary HealthJTO Clinical and Research Reports is an esteemed open-access journal published by Elsevier, dedicated to advancing knowledge in the fields of Oncology and Pulmonary and Respiratory Medicine. Since its inception in 2020, the journal has rapidly gained recognition, achieving a commendable Q1 ranking in both fields as of 2023, highlighting its significant contribution to high-quality research and clinical practice. With an inclusive global reach, JTO Clinical and Research Reports fosters collaboration by allowing unrestricted access to its content, ensuring that vital research findings can be disseminated widely among researchers, clinicians, and students alike. Located in the United States, and with its editorial base in the Netherlands, this journal not only embraces the mission of open science but also strives to publish impactful studies that address critical challenges in cancer treatment and respiratory health. Through its rigorous peer-review process and commitment to excellence, JTO Clinical and Research Reports aims to be at the forefront of scientific discourse and innovation in these dynamic areas of medicine.
HEPATOLOGY
Transforming liver health with groundbreaking insights.HEPATOLOGY is a premier scholarly journal dedicated to advancing the field of liver research and clinical practice. Published by Lippincott Williams & Wilkins, this journal boasts an impressive impact factor and holds a prestigious position as one of the top-ranked publications in both Hepatology (Q1) and Medicine (miscellaneous, Q1) categories as of 2023. HEPATOLOGY, with its commitment to disseminating high-quality research since its inception in 1981, serves as an essential platform for researchers, clinicians, and students focusing on liver diseases, including hepatitis, cirrhosis, and liver cancer. The journal's editorial board comprises leading experts who guide the publication towards its objective of fostering innovation and collaboration in this critical area of health. Although it does not offer an open access model, HEPATOLOGY ensures that its comprehensive analyses, reviews, and groundbreaking studies are accessible to the global medical community. Join the discourse in hepatology and be a part of a transformative journey through this indispensable resource.
CANCER RESEARCH
Shaping the future of cancer research with excellence.Cancer Research, published by the American Association for Cancer Research, is a premier journal in the field of oncology, renowned for its commitment to advancing cancer research since its inception in 1941. With an impressive impact factor reflecting its vital role in the field, this journal consistently ranks in the Q1 quartile for both Cancer Research and Oncology, positioning it among the top 7.5% of journals in these categories. The journal serves as a crucial platform for researchers, professionals, and students to disseminate and gain insights into groundbreaking studies that shape our understanding of cancer biology, prevention, diagnosis, and treatment. While it is not an open-access publication, its rigorous peer-review process ensures that only high-quality research is published, thus maintaining a standard of excellence in the scientific community. With a strong legacy and an ever-expanding influence, Cancer Research continues to be essential for anyone dedicated to the fight against cancer, showcasing cutting-edge research that drives scientific discovery and innovation.
Oncology Research and Treatment
Empowering the future of oncology with cutting-edge insights.Oncology Research and Treatment, published by KARGER, is a highly regarded academic journal dedicated to advancing the field of oncology through rigorous research and clinical insights. With a history spanning from 1978 to 1997 and continuing from 2013 to 2024, this journal provides a vital platform for researchers and professionals in cancer research, hematology, and related disciplines. Though currently listed in the Q3 tier of 2023 for Cancer Research, Hematology, and Oncology, its growing readership and open access policy enhance its visibility and impact within the scientific community. Based in Switzerland, the journal features diverse access options, reflecting the global importance of oncology research. With a focus on innovative treatments and the latest methodologies, Oncology Research and Treatment plays a crucial role in fostering collaboration and dialogue among researchers, professionals, and students alike, helping to shape the future of cancer care and management.
Hepatic Oncology
Elevating Research on Hepatic MalignanciesHepatic Oncology is a premier Open Access journal published by Future Medicine Ltd that specializes in the critical intersection of hepatology and oncology. With a focus on advancing knowledge in the diagnosis and treatment of liver cancers, the journal provides a platform for innovative research, reviews, and clinical perspectives that serve as a valuable resource for researchers, clinicians, and students alike. Established in 2016 and evolving over the years, Hepatic Oncology underscores its commitment to accessible scientific communication, having transitioned to open access in 2018 to reach a broader audience. The journal holds a Q4 quartile ranking in the fields of hepatology and oncology for 2023, reflecting its emerging influence and role in contemporary research. Through high-quality articles and a focus on real-world applications, Hepatic Oncology aims to bridge gaps in knowledge while fostering collaboration among professionals dedicated to enhancing patient care in hepatic malignancies.
LIVER INTERNATIONAL
Shaping the future of hepatology with impactful discoveries.LIVER INTERNATIONAL, with its ISSN 1478-3223 and E-ISSN 1478-3231, is a prestigious peer-reviewed journal published by Wiley in the United Kingdom. Established in 2003, it focuses on advancing the field of hepatology, covering a broad spectrum of topics including liver disease, hepatocellular carcinoma, and transplantation. Ranking #10 out of 82 in the Scopus category for Medicine - Hepatology and boasting a remarkable 88th percentile, LIVER INTERNATIONAL has secured its reputation as a leading journal, recognized as Q1 in the 2023 category quartiles. The journal emphasizes accessibility, offering an open access option to ensure that critical research findings reach a wider audience. By facilitating the dissemination of high-quality research, LIVER INTERNATIONAL plays a vital role in shaping contemporary hepatological discourse and bridging academic inquiry with clinical practice, making it an essential resource for researchers, healthcare professionals, and students alike.
Liver Cancer
Exploring innovative treatments and strategies for liver cancer.Liver Cancer is a premier, peer-reviewed journal dedicated to the comprehensive study and advancement of knowledge surrounding liver neoplasms. Published by KARGER and headquartered in Switzerland, this journal has been an open-access platform since 2012, providing researchers with invaluable insights into the rapidly evolving field of hepatology and oncology. With an impressive impact factor that places it in the Q1 category for both Hepatology and Oncology in 2023, Liver Cancer stands out as a high-impact conduit for groundbreaking research, ranking #19 out of 404 in Medicine _ Oncology and #6 out of 82 in Medicine _ Hepatology according to Scopus. Researchers, practitioners, and students are encouraged to engage with the journal's content, which encompasses clinical studies, basic research, and reviews that contribute significantly to understanding liver cancer dynamics, diagnosis, and treatment strategies. This journal not only facilitates the dissemination of knowledge but also fosters collaboration in a well-established and impactful global scientific community.
Annual Review of Cancer Biology
Bridging Academia and Clinical Applications in Cancer ResearchAnnual Review of Cancer Biology is a pivotal journal published by Annual Reviews, specializing in the rapidly evolving field of cancer research. With an impact factor positioned in the distinguished Q1 quartile of Cancer Research, Cell Biology, and Oncology categories, this journal ensures that it showcases the highest quality of scholarly contributions. Indexed in Scopus, it ranks among the top in its fields, reflecting its strong influence and relevance, with remarkable percentiles indicating its esteemed position within the research community. Although not an open-access journal, it provides a comprehensive platform for advancing the frontiers of cancer biology through rigorously curated reviews, highlighting key developments, breakthroughs, and future directions that inform both academia and clinical applications. As a valuable resource for researchers, professionals, and students, the Annual Review of Cancer Biology serves as an essential guide for understanding and addressing the complexities of cancer biology today.
JHEP Reports
Advancing healthcare knowledge through open access.JHEP Reports, published by ELSEVIER, stands at the forefront of scholarly communication in the fields of Gastroenterology, Hepatology, Immunology and Allergy, and Internal Medicine. As an Open Access journal since 2019, it provides a platform for the dissemination of high-quality research findings, making vital information readily accessible to a global audience. With a commendable impact characterized by a Q1 category ranking across four medical disciplines in 2023, JHEP Reports demonstrates its significance and influence, reflected in its impressive Scopus ranks—#11 in Gastroenterology and #14 in Internal Medicine, amongst others. This esteemed journal not only plays a critical role in advancing knowledge but also fosters collaboration among researchers, practitioners, and students keen on exploring innovations and breakthroughs in health sciences. At RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS, JHEP Reports is committed to bridging the gap between research and application, ushering in a new era of informed and effective healthcare solutions.
Oncologie
Pioneering insights in the fight against cancer.Oncologie is a distinguished academic journal published by WALTER DE GRUYTER GMBH, focusing on the dynamic and vital field of oncology. Established in 1999 and continuously published until 2024, this journal provides a platform for high-quality research and advancements in cancer treatment, prevention, and diagnosis. With an ISSN of 1292-3818 and an E-ISSN of 1765-2839, it is indexed in various databases, contributing to its growing visibility. Although categorized in the Q3 quartile for oncology research as of 2023, Oncologie offers essential insights and fosters scholarly dialogue among researchers, professionals, and students interested in oncology. Its unique contributions aim to bridge the gap between theoretical frameworks and clinical applications, making it a valuable resource for those seeking to advance their knowledge and expertise in cancer research.